Stock listing

NASDAQ:TRAX First Tracks Biotherapeutics, Inc. Stock

Home listing (NASDAQ) of First Tracks Biotherapeutics, Inc.

Follow First Tracks Biotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TRAX

$36.28 USD +1.82 (+5.3%)

Close on Oct 19, 2026

Since Jul 6, 2026 +81.0% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$35.00 – $37.23 USDOct 19, 2026
Volume
1.43M sharesOct 19, 2026
Market value
$1.30B USDAt the close on Oct 19, 2026 · price × 35.73M shares outstanding
Ticker
NASDAQ:TRAX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

First Tracks Biotherapeutics Announces $200 Million Private Placement

Oct 15, 2026

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

Oct 12, 2026

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Oct 11, 2026

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

Aug 26, 2026

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

May 21, 2026

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

Apr 20, 2026

All First Tracks Biotherapeutics, Inc. news

Financings

  • Private placement of shares of common stock

    Oct 15, 2026

    Announced: about US$200M · US$32.75 a share · Leerink Partners +3

    Dealers: Leerink Partners, Piper Sandler, UBS Investment Bank, Wells Fargo Securities

    Buyers: Affinity Asset Advisors, LLC; First Light Asset Management; Sirenia Capital Management LP; TCGX; Trails Edge Capital Partners; Vestal Point Capital

    Use of proceeds: General corporate purposes, including clinical development of ANB033, a CD122 antagonist

    Announced Oct 15, 2026

Read by 6ix AI from the company's releases

Decks

First Tracks Biotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
8 in the last 12 months · 8 in all · newest Oct 15, 2026 · oldest 2026
Decks
1 deck · latest Oct 13, 2026

Where First Tracks Biotherapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TRAX · Home listing · This pageNASDAQUnited StatesUSD
BMV:TRAXBMVMexicoMXN
BOATS:TRAXBOATSUnited StatesUSD
BIVA:TRAXBIVAMexicoMXN
Dusseldorf:B43DusseldorfGermanyUSD
Hamburg:B43HamburgGermanyEUR

Log in to ask 6ix AI your own questions about First Tracks Biotherapeutics, Inc.